S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA News Today

$39.60
-0.09 (-0.23%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$38.86
$40.45
50-Day Range
$39.60
$54.59
52-Week Range
$37.59
$79.50
Volume
172,108 shs
Average Volume
177,520 shs
Market Capitalization
$827.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.60
Get Enanta Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.


ENTA Media Mentions By Week

ENTA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ENTA
News Sentiment

-0.18

0.35

Average
Medical
News Sentiment

ENTA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ENTA Articles
This Week

11

2

ENTA Articles
Average Week

SourceHeadline
marketbeat.com logoHennion & Walsh Asset Management Inc. Lowers Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
marketbeat.com - March 23 at 5:18 AM
MarketBeat logoEnanta Pharmaceuticals' (ENTA) "Sector Perform" Rating Reaffirmed at Royal Bank of Canada
americanbankingnews.com - March 23 at 5:40 AM
markets.businessinsider.com logoExpert Ratings for Enanta Pharma
markets.businessinsider.com - March 22 at 7:53 PM
MarketBeat logoInsider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Sells $618,966.25 in Stock
americanbankingnews.com - March 20 at 5:06 AM
MarketBeat logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $68.60 Consensus Price Target from Brokerages
americanbankingnews.com - March 20 at 2:02 AM
MarketBeat logoInsider Selling: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Sells $1,260,505.92 in Stock
americanbankingnews.com - March 17 at 4:38 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
finance.yahoo.com - March 8 at 7:21 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
finance.yahoo.com - March 7 at 10:08 AM
finance.yahoo.com logoEnanta Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations
finance.yahoo.com - February 9 at 3:17 PM
finance.yahoo.com logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcript
finance.yahoo.com - February 8 at 6:48 PM
finance.yahoo.com logoThese Analysts Just Made A Huge Downgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) EPS Forecasts
finance.yahoo.com - February 8 at 1:47 PM
finance.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
finance.yahoo.com - February 7 at 5:16 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
finance.yahoo.com - February 7 at 7:15 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
finance.yahoo.com - January 31 at 8:33 AM
nasdaq.com logoEnanta Pharmaceuticals (ENTA) Shares Cross Above 200 DMA
nasdaq.com - January 24 at 9:07 PM
markets.businessinsider.com logoSVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
markets.businessinsider.com - January 16 at 10:05 AM
markets.businessinsider.com logoAnalysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Enanta Pharmaceuticals (ENTA) and Day One Biopharmaceuticals (DAWN)
markets.businessinsider.com - January 10 at 1:01 PM
finance.yahoo.com logoAn Intrinsic Calculation For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Suggests It's 49% Undervalued
finance.yahoo.com - January 6 at 9:00 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 9:00 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 10:25 AM
seekingalpha.com logoEnanta: Deep Losses In FY 2022 Look To Be Justified Given Macro Landscape
seekingalpha.com - December 30 at 1:34 PM
finance.yahoo.com logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call Transcript
finance.yahoo.com - December 25 at 1:44 PM
finance.yahoo.com logoNewsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue Forecasts
finance.yahoo.com - November 23 at 6:52 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Participate in Two Investor Conferences in November
finance.yahoo.com - November 22 at 10:36 AM
seekingalpha.com logoEnanta Pharmaceuticals, Inc. (ENTA) Q4 2022 Earnings Call Transcript
seekingalpha.com - November 21 at 9:14 PM
finance.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
finance.yahoo.com - November 21 at 4:13 PM
benzinga.com logoEarnings Outlook For Enanta Pharmaceuticals
benzinga.com - November 18 at 10:42 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022
finance.yahoo.com - November 14 at 10:53 AM
finance.yahoo.com logoEnanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
finance.yahoo.com - November 9 at 7:22 AM
finance.yahoo.com logoInvestors in Enanta Pharmaceuticals (NASDAQ:ENTA) have unfortunately lost 51% over the last year
finance.yahoo.com - November 3 at 2:54 PM
finance.yahoo.com logoEnanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022
finance.yahoo.com - October 19 at 9:56 AM
finance.yahoo.com logoEnanta Pharmaceuticals, Inc. (ENTA)
finance.yahoo.com - October 17 at 5:31 PM
finance.yahoo.com logoEnanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
finance.yahoo.com - October 17 at 9:22 AM
finance.yahoo.com logoEnanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
finance.yahoo.com - October 3 at 7:53 AM
finance.yahoo.com logoEnanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
finance.yahoo.com - September 29 at 11:14 AM
finance.yahoo.com logoEnanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
finance.yahoo.com - September 22 at 10:23 AM
finance.yahoo.com logoNew Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
finance.yahoo.com - September 7 at 11:32 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Participate in Two Investor Conferences in September
finance.yahoo.com - September 1 at 7:31 AM
finance.yahoo.com logoNeed To Know: Analysts Just Made A Substantial Cut To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates
finance.yahoo.com - August 14 at 6:51 PM
finance.yahoo.com logoThe Petri Dish: Cyteir puts a drug on pause, Alexion vet joins Watertown biotech
finance.yahoo.com - August 11 at 5:49 PM
nasdaq.com logoEnanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
nasdaq.com - August 9 at 8:18 PM
finance.yahoo.com logoEnanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcript
finance.yahoo.com - August 9 at 2:47 AM
seekingalpha.com logoEnanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcript
seekingalpha.com - August 8 at 9:41 PM
finance.yahoo.com logoEnanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - August 8 at 9:41 PM
finance.yahoo.com logoEnanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
finance.yahoo.com - August 8 at 4:40 PM
finance.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
finance.yahoo.com - August 8 at 4:40 PM
MarketBeat logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokerages
americanbankingnews.com - August 4 at 1:12 AM
nasdaq.com logoBullish Two Hundred Day Moving Average Cross - ENTA
nasdaq.com - August 3 at 8:24 PM
markets.businessinsider.com logoWhat 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals
markets.businessinsider.com - August 1 at 7:10 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
finance.yahoo.com - August 1 at 8:07 AM
markets.businessinsider.com logoEnanta Shares Rise On Positive Data From Initial-Stage Covid Study
markets.businessinsider.com - July 29 at 3:31 PM
Get Enanta Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ENTA) was last updated on 3/24/2023 by MarketBeat.com Staff